Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease
Published
ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer's disease. Neurimmune…
#zurich #switzerland #neurimmune #fda #biogen #ip #gmp #christophhock #brain #fabianbuller